[go: up one dir, main page]

PE20211550A1 - Pamoato de ketamina y su uso - Google Patents

Pamoato de ketamina y su uso

Info

Publication number
PE20211550A1
PE20211550A1 PE2021000756A PE2021000756A PE20211550A1 PE 20211550 A1 PE20211550 A1 PE 20211550A1 PE 2021000756 A PE2021000756 A PE 2021000756A PE 2021000756 A PE2021000756 A PE 2021000756A PE 20211550 A1 PE20211550 A1 PE 20211550A1
Authority
PE
Peru
Prior art keywords
pamoate
ketamine
salts
ketamine pamoate
anesthetic
Prior art date
Application number
PE2021000756A
Other languages
English (en)
Inventor
Tong-Ho Lin
Yung-Shun Wen
Chia-Hsien Chen
Wei-Ju Chang
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of PE20211550A1 publication Critical patent/PE20211550A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan sales de pamoato de ketamina que tienen una estequiometria de 2:1 de ketamina a pamoato, incluyendo pamoato de R, S-ketamina, pamoato de S-ketamina, o pamoato de R-ketamina, y formas cristalinas o amorfas de las sales de pamoato, y que tienen excelente seguridad y propiedades para aplicaciones farmaceuticas. Tambien se proporcionan composiciones farmaceuticas que incluyen las sales de pamoato de la ketamina y sus usos en el tratamiento de una enfermedad del SNC o como anestesico.
PE2021000756A 2019-01-11 2020-01-10 Pamoato de ketamina y su uso PE20211550A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791058P 2019-01-11 2019-01-11
US201962871763P 2019-07-09 2019-07-09
PCT/CN2020/071404 WO2020143762A1 (en) 2019-01-11 2020-01-10 Ketamine pamoate and use thereof

Publications (1)

Publication Number Publication Date
PE20211550A1 true PE20211550A1 (es) 2021-08-16

Family

ID=71521952

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000756A PE20211550A1 (es) 2019-01-11 2020-01-10 Pamoato de ketamina y su uso

Country Status (27)

Country Link
US (1) US11981617B2 (es)
EP (1) EP3908570B1 (es)
JP (1) JP7451538B2 (es)
KR (1) KR20210116517A (es)
CN (1) CN113423686B (es)
AU (1) AU2020206826B2 (es)
CA (1) CA3118954A1 (es)
CL (1) CL2021001803A1 (es)
CO (1) CO2021006884A2 (es)
DK (1) DK3908570T3 (es)
ES (1) ES2974259T3 (es)
FI (1) FI3908570T3 (es)
HR (1) HRP20240255T1 (es)
HU (1) HUE065684T2 (es)
LT (1) LT3908570T (es)
MX (1) MX2021006029A (es)
PE (1) PE20211550A1 (es)
PH (1) PH12021551157A1 (es)
PL (1) PL3908570T3 (es)
PT (1) PT3908570T (es)
RS (1) RS65271B1 (es)
SG (1) SG11202104792SA (es)
SI (1) SI3908570T1 (es)
SM (1) SMT202400100T1 (es)
TW (1) TWI827783B (es)
WO (1) WO2020143762A1 (es)
ZA (1) ZA202103132B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
JP2023505963A (ja) * 2019-12-20 2023-02-14 ▲ユ▼展新藥生技股分有限公司 ケタミンパモエート塩の長時間作用型注射用製剤
US20210322669A1 (en) * 2020-04-16 2021-10-21 Invictus Health, Inc. Method for treatment of traumatic brain injuries
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107456A (pt) 2000-01-07 2002-10-08 Transform Pharmaceuticals Inc Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US9421266B2 (en) * 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
JO2857B1 (en) 2008-06-16 2015-03-15 سانوفي أفينتس Vinyl pipers with modified activity of tumor-resistant TNF
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JP2014196292A (ja) 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017167180A1 (zh) 2016-03-29 2017-10-05 上海华汇拓医药科技有限公司 沃替西汀的帕莫酸盐及其晶型
KR102422382B1 (ko) * 2016-12-26 2023-01-25 셀릭스 바이오 프라이빗 리미티드 통증 치료를 위한 조성물
CN111836798B (zh) * 2018-01-10 2022-04-15 凯瑞康宁生物工程（武汉）有限公司 氯胺酮的前药、其组合物和用途

Also Published As

Publication number Publication date
US20220119338A1 (en) 2022-04-21
EP3908570A4 (en) 2022-10-19
JP7451538B2 (ja) 2024-03-18
EP3908570B1 (en) 2023-12-13
JP2022518003A (ja) 2022-03-11
CN113423686B (zh) 2023-08-22
CL2021001803A1 (es) 2021-12-24
CO2021006884A2 (es) 2021-06-10
WO2020143762A1 (en) 2020-07-16
DK3908570T3 (da) 2024-02-26
SMT202400100T1 (it) 2024-05-14
CA3118954A1 (en) 2020-07-16
AU2020206826B2 (en) 2024-05-02
FI3908570T3 (fi) 2024-02-13
LT3908570T (lt) 2024-03-12
RS65271B1 (sr) 2024-03-29
NZ775810A (en) 2024-07-26
PL3908570T3 (pl) 2024-07-01
KR20210116517A (ko) 2021-09-27
MX2021006029A (es) 2021-09-23
HRP20240255T1 (hr) 2024-05-24
HUE065684T2 (hu) 2024-06-28
ES2974259T3 (es) 2024-06-26
EP3908570A1 (en) 2021-11-17
BR112021013340A2 (pt) 2021-09-14
CN113423686A (zh) 2021-09-21
PT3908570T (pt) 2024-03-15
PH12021551157A1 (en) 2021-11-03
ZA202103132B (en) 2024-11-27
TW202042796A (zh) 2020-12-01
TWI827783B (zh) 2024-01-01
SG11202104792SA (en) 2021-06-29
AU2020206826A1 (en) 2021-06-03
US11981617B2 (en) 2024-05-14
SI3908570T1 (sl) 2024-04-30

Similar Documents

Publication Publication Date Title
CL2021001803A1 (es) Pamoato de ketamina y su uso
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018002060A2 (es) Compuestos farmacéuticos
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX2017007658A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo.
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
CO6690805A2 (es) 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2021000930A1 (es) Piridazinas novedosas
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.